A Multicenter Investigation with D-FISH BCR/ABL1 Probes

• Published in: Cancer genetics and cytogenetics Vol. 116; no. 2; pp. 97 - 104
• Main Authors: Dewald, Gordon, Stallard, Richard, Alsaadi, A., Arnold, Susan, Blough, Ruthann, Ceperich, Tina M., Elejalde, B.Rafael, Fink, James, Higgins, James V., Higgins, Rodney R., Hoeltge, Gerald A., Hsu, Wei-Tong, Johnson, Eric B., Kronberger, Diane, McCorquodale, D.James, Meisner, Lorraine F., Micale, Mark A., Oseth, LeAnn, Payne, Janet S., Schwartz, Stuart, Sheldon, Susan, Sophian, Ardis, Storto, Patrick, Van Tuinen, Peter, Wenger, Gail D., Wiktor, Ann, Willis, Leslie A., Yung, Jar-Fee, Zenger-Hain, Julie
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15-01-2000; Elsevier Science
• Subjects: Biological and medical sciences; Bone Marrow - pathology; Clinical Laboratory Techniques - standards; Fluorescent Dyes; Fusion Proteins, bcr-abl - genetics; Hematologic and hematopoietic diseases; Humans; In Situ Hybridization, Fluorescence - instrumentation; In Situ Hybridization, Fluorescence - methods; In Situ Hybridization, Fluorescence - standards; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Quality Control; Sensitivity and Specificity; Workload; Human; Molecular hybridization; Multicenter study; In situ; Fluorescence; Exploration; Malignant hemopathy; Myeloproliferative syndrome; Quality assurance; Chronic; Chronic myelocytic leukemia; Genetics; Technique; Molecular biology
• ISSN: 0165-4608; 1873-4456
• DOI: 10.1016/S0165-4608(99)00120-X

Twenty-eight laboratories evaluated a new fluorescence in situ hybridization (FISH) strategy for chronic myeloid leukemia. In a three-part study, bcr/abl1 D-FISH probes were used to study bone marrow specimens. First, laboratories familiarized themselves with the strategy by applying it to known normal and abnormal specimens. Then, collectively the laboratories studied 20 normal and 20 abnormal specimens blindly and measured workload. Finally, each laboratory and two experts studied six serial dilutions with 98–0% abnormal nuclei. Using the reported normal cutoff of <1% abnormal nuclei, participants reported no false-negative cases and 15 false-positive cases (1–6.6% abnormal nuclei). Results provided by participants for serial dilutions approximated the expected percentages of abnormal nuclei, but those from the experts exhibited greater precision. The clinical sensitivity, precision, nomenclature, workload, recommendations for training, and quality assurance in methods using D-FISH in clinical practice are discussed.